HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beiersdorf To Enter US Sun Care With Curiously Timed Coppertone Acquisition

Executive Summary

The Germany-based skin-care specialist will pay Bayer $550m for the iconic brand and gain entry to the US sunscreen market. The US represents the world’s biggest opportunity for sun care, but it’s also rife with uncertainty following FDA’s recent call for data to support key active ingredients’ continued GRASE status.

You may also be interested in...



US Demand For Eucerin Drives Beiersdorf To Spread Brand Into Sun Care, Post-Acne

Beiersdorf extends Eucerin line combining skin treatment with sun care and moves the brand into post-acne category using Thiamidol ingredient. Eucerin and Aquaphor brand sales grew 18.2% in its latest quarter.

Coppertone’s Dismissal Motion Shut Down In False-Advertising Action Over ‘Mineral-Based’ Claims

Plaintiffs allege that Coppertone sunscreens are deceptively labeled as “mineral-based” when they contain a larger percentage of chemical active ingredients than mineral active ingredients. On 31 July, California’s Northern District roundly rejected defendants’ motion to dismiss.

Coppertone ‘Mineral-Based’ Sunscreens Are Falsely Advertised – Proposed Class Action

The iconic sunscreen brand aims to capitalize on growing demand for mineral sunscreens – widely perceived as consumers’ safest option in sun defense – by positioning offerings that contain mixes of mineral and chemical UV filters as “mineral-based,” according to a suit filed in December in California federal court.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS148809

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel